08045804946
medisus.pharma007@gmail.com
Change Language
FULZOS 250MG INJ

FULZOS 250MG INJ

2800.0 INR/Box

Product Details:

  • Life Span 24 months from manufacturing date
  • Salt Composition Fulvestrant 250mg
  • Origin of Medicine India
  • Dosage Form Parenteral injection
  • Pacakaging (Quantity Per Box) 1 vial per box
  • Indication Hormone receptor-positive metastatic breast cancer in postmenopausal women
  • Packaging Type Vial with outer carton
  • Click to View more
X

FULZOS 250MG INJ Price And Quantity

  • 2800.0 INR/Box
  • 1 Number

FULZOS 250MG INJ Product Specifications

  • Store below 25C. Protect from light. Do not freeze.
  • FULZOS 250MG INJ
  • Vial with outer carton
  • Injection
  • 1 vial
  • Administer under the supervision of a registered medical practitioner
  • Antineoplastic (breast cancer treatment)
  • Hormone receptor-positive metastatic breast cancer in postmenopausal women
  • Adults
  • Parenteral injection
  • 1 vial per box
  • 250 mg administered intramuscularly
  • India
  • Fulvestrant 250mg
  • Allopathic
  • Adults, mainly postmenopausal women with hormone receptor-positive metastatic breast cancer
  • Fulvestrant 250mg per vial
  • 24 months from manufacturing date
  • Celon Laboratories Ltd.
  • As directed by oncologist
  • Anticancer
  • Injection site pain, hot flashes, nausea, fatigue
  • Intramuscular (IM)
  • For hospital use only, not for self-administration
  • Hypersensitivity to fulvestrant or any excipients
  • Yes
  • 2 years from date of manufacture
  • Clear, colorless to yellowish, viscous liquid

FULZOS 250MG INJ Trade Information

  • 1000 Number Per Week
  • 2 Days
  • No
  • Asia, Middle East, Africa, Australia, Central America, North America, South America, Eastern Europe, Western Europe
  • All India

Product Description

  • Active Ingredient: Fulvestrant 250 mg/5 ml solution for injection.
  • Class: Estrogen receptor antagonist (an estrogen blocker) and antineoplastic drug.
  • How it Works: Many breast cancers have estrogen receptors and depend on the hormone estrogen to grow. Fulvestrant works by binding to these estrogen receptors and blocking the action of estrogen on the cancer cells. This causes the receptors to degrade, slowing down or stopping the growth of the tumor cells.
Uses
Fulzos 250 mg is used in postmenopausal women with:
  • Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer.
  • Cancer that has progressed after prior treatment with other anti-estrogen medications.
  • It may be used alone (monotherapy) or in combination with other anti-cancer medications like palbociclib or abemaciclib


Specialized Cancer Care for Women

FULZOS 250MG INJ is specifically formulated for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women. By targeting hormone receptors, it helps slow cancer progression and can improve outcomes in eligible patients. It is part of a comprehensive treatment plan developed by oncologists to address advanced breast cancer.


Safe Administration and Handling

FULZOS 250MG INJ must only be given by registered medical professionals in a hospital setting. The injection is administered intramuscularly, ensuring the medicine is delivered efficiently into the body. Strict adherence to storage and administration guidelines guarantees the product's effectiveness and patient safety.


Quality Assurance and Storage

Each vial of FULZOS comes securely packaged, with a shelf life of 24 months from the date of manufacture when stored below 25C and protected from light. The clear to yellowish solution is easy to visually inspect for quality before use, and healthcare professionals ensure the correct dosage and handling every time.

FAQ's of FULZOS 250MG INJ:


Q: How should FULZOS 250MG INJ be administered?

A: The injection is administered as a 250 mg intramuscular dose by a registered medical practitioner, typically into the buttock muscle, in a hospital or oncology clinic. Self-administration is not recommended.

Q: What is the main therapeutic use of FULZOS 250MG INJ?

A: FULZOS 250MG INJ is used to treat hormone receptor-positive metastatic breast cancer in postmenopausal women as directed by an oncologist.

Q: When is the best time to receive this medication?

A: The timing and frequency are determined by the oncologist's protocol. It is usually given at regular intervals as part of a scheduled cancer treatment plan.

Q: Where should FULZOS 250MG INJ be stored before use?

A: Store the injection below 25C, protected from light, and never freeze it. Pharmacy staff ensure proper storage before administration.

Q: What are the possible side effects of this medicine?

A: Common side effects include injection site pain, hot flashes, nausea, and fatigue. Inform your healthcare provider if you experience any unusual symptoms.

Q: Who should not receive FULZOS 250MG INJ?

A: People with known hypersensitivity to fulvestrant or any excipients in FULZOS should not receive this injection. Always consult your oncologist about your medical history.

Q: What are the benefits of using FULZOS 250MG INJ?

A: The main benefit is its targeted action against hormone receptor-positive metastatic breast cancer, helping to slow down or stop the growth of cancer cells in postmenopausal women.

Tell us about your requirement
product

Price:

Quantity
Select Unit

  • 50
  • 100
  • 200
  • 250
  • 500
  • 1000+
Additional detail
Mobile number

Email

Other Products in 'Anti Cancer Medicines' category



Back to top